drugset / Trial / NCT04709094
A Drug Interaction Study of Danicopan
Phase 1
Completed
52 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collabCelerion · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
This was a 3-part study (Part 1, Part 2, Part 3) with each part being an open-label, fixed sequence, 2-period study in healthy adult participants.
Timeline
- Start
- 2019-07-28
- Primary completion
- 2019-10-14
- Completion
- 2020-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | 100 mg | — |
| Subject | Danicopan | Small molecule | 200 mg | — |
| Subject | Norethindrone | Unknown | 1 mg | Oral |
| Subject | Warfarin | Small molecule | 25 mg | — |
| Subject | ethinyl estradiol | Small molecule | 0.035 mg | Oral |
Indications
No indication recorded.